There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.
advertisement
What Biotech Companies Want in Generic Legislation
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
CME/CE
Updates From the 7th World Symposium Task Force
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">Updates From the 7th World Symposium Task Force</span><span data-ccp-props='{"201341983":0,"335559738":210,"335559739":210,"335559740":240}'> </span></p>
CME/CE
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
0.50 credits
<p>TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management</p>
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 credits
<p>A Practical Guide to Prescribing in HF</p>
MinuteCE®
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
1.25 credits
<p>Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA</p>
MinuteCE®
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
1.25 credits
<p>Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation</p>
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?